New Data Highlighting Foundation Medicine's Second Clinical Product to be Presented at American Society of Hematology Annual Meeting
"We are making progress toward the introduction of our second clinical product, FoundationOne™ Heme, by early 2014 and look forward to sharing initial data with the hematology community at this year's ASH meeting," stated
The schedule for oral presentations by
Date & Time:
Title: Identification of Actionable Genomic Alterations in Hematologic Malignancies by a Clinical Next Generation Sequencing-Based Assay
Abstract number: 230
Session: 611. Leukemias: Biology, Cytogenetics and Molecular Markers in Diagnosis and Prognosis: Genomic Alterations in Acute Lymphoblastic Leukemia--Implications for Pathogenesis, Prognosis and Therapy
Type: Oral Presentation
Location:
Collaborator:
Date & Time:
Title: Overview of The Genomic Landscape of High Risk Diffuse Large B-Cell Lymphoma Using Targeted DNA and RNA Sequencing
Abstract number: 501
Session: 622. Non-Hodgkin Lymphoma: Biology, Excluding Therapy: Genomics
Type: Oral Presentation
Location:
Collaborator:
Date & Time:
Title: Pilot Study to Evaluate The Prevalence of Actionable Oncogenic Mutations in Patients with Relapsed Refractory Multiple Myeloma
Abstract number: 755
Session: 651. Myeloma: Biology and Pathophysiology, excluding Therapy: Microenvironment
Type: Oral Presentation
Location:
Collaborator:
The schedule for poster presentations by
Date & Time:
Title: Patient Derived Xenograft (PDX) Models Faithfully Recapitulated The Genetic Composition of Primary AML
Abstract number: 1328
Session: 611. Leukemias: Biology, Cytogenetics and Molecular Markers in Diagnosis and Prognosis: Poster I
Type: Poster Session
Location: Hall E
Collaborator:
Date & Time:
Title: Integrated Genetic Profiling Of JAK2 Wildtype Chronic-Phase Myeloproliferative Neoplasms
Abstract number: 1588
Session: 634. Myeloproliferative Syndromes: Clinical: Poster I
Type: Poster Session
Location: Hall E
Collaborator:
Date & Time:
Title: Profiling Genomic Alterations of Diffuse Large B-Cell Lymphoma (DLBCL) At Diagnosis, Relapse, and Transformation, Using a Novel Clinical Diagnostic Targeted Sequencing Platform
Abstract number: 1761
Session: 622. Non-Hodgkin Lymphoma: Biology, Excluding Therapy: Poster I
Type: Poster Session
Location: Hall G
Collaborator:
Date & Time:
Title: Mutational Profiling of Myeloid Malignancies for Prediction of Disease Relapse Following Allogeneic Stem Cell Transplantation
Abstract number: 2096
Session: 731. Clinical Allogeneic and Autologous Transplantation - Results: Poster I
Type: Poster Session
Location: Hall G
Collaborator:
Date & Time:
Title: Comprehensive Mutational Profiling in Myelodysplastic Syndromes Treated with Decitabine and Tretinoin
Abstract number: 2791
Session: 633. Myelodysplastic Syndromes: Poster II
Type: Poster Session
Location: Hall E
Collaborator:
Date & Time:
Title: Extensive High-Depth Sequencing of Longitudinal CLL Samples Identifies Frequent Mutations in MAP Kinase Signaling and Novel Mutations Activating Notch and Beta-Catenin
Abstract number: 2858
Session: 641. CLL: Biology and Pathophysiology, excluding Therapy: Poster II
Type: Poster Session
Location: Hall E
Collaborator:
Date & Time:
Title: High-Throughput Mutational Profiling Of Post-Myeloproliferative Neoplasm Acute Myeloid Leukemia Reveals Frequent Mutations In NRAS In JAK2V617F-Negative Post-MPN AML
Abstract number: 4098
Session: 635. Myeloproliferative Syndromes: Basic Science: Poster III
Type: Poster Session
Location: Hall E
Collaborator:
About
Foundation Medicine® is a registered trademark, and FoundationOneTM is a trademark, of
Cautionary Note Regarding Forward-Looking Statements
This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding the benefits to patients of next-generation sequencing of their tumors and blood based cancers, clinical data related to Foundation Medicine's products, Foundation Medicine's plans or ability to develop and commercialize new products, including the commercial launch of FoundationOneTM Heme, and Foundation Medicine's participation in the ASH annual meeting. All such forward-looking statements are based on management's current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include the risks that FoundationOneTM, FoundationOneTM Heme and any subsequent products may never achieve significant commercial adoption or reimbursement support;
Media Contact:
dan@purecommunicationsinc.com
or
Investor Contact:
ir@foundationmedicine.com
Source:
News Provided by Acquire Media